MENU
+Compare
FENC
Stock ticker: NASDAQ
AS OF
Sep 16, 04:59 PM (EDT)
Price
$8.82
Change
+$0.15 (+1.73%)
Capitalization
248.34M

FENC Fennec Pharmaceuticals Forecast, Technical & Fundamental Analysis

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company... Show more

Industry: #Biotechnology
FENC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for FENC with price predictions
Sep 15, 2025

FENC's Stochastic Oscillator descends into oversold zone

The Stochastic Oscillator for FENC moved into oversold territory on September 15, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

FENC moved above its 50-day moving average on August 22, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FENC crossed bullishly above the 50-day moving average on August 29, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FENC advanced for three days, in of 270 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 11, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on FENC as a result. In of 113 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FENC turned negative on September 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FENC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FENC broke above its upper Bollinger Band on August 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for FENC entered a downward trend on August 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FENC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FENC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (52.910) is normal, around the industry mean (20.594). P/E Ratio (64.143) is within average values for comparable stocks, (53.282). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.156). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (7.305) is also within normal values, averaging (342.112).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
FENC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

FENC is expected to report earnings to fall 172.73% to 7 cents per share on November 06

Fennec Pharmaceuticals FENC Stock Earnings Reports
Q3'25
Est.
$0.08
Q2'25
Missed
by $0.07
Q1'25
Beat
by $0.06
Q4'24
Beat
by $0.07
Q3'24
Missed
by $0.11
The last earnings report on August 14 showed earnings per share of -10 cents, missing the estimate of -3 cents. With 56.50K shares outstanding, the current market capitalization sits at 248.34M.
A.I. Advisor
published General Information

General Information

a developer of therapeutic products based on cell adhesion

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
68 TW Alexander Drive
Phone
+1 919 636-4530
Employees
29
Web
https://www.fennecpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ATUSF22.500.13
+0.58%
Altius Minerals Corp.
DNTUY21.670.09
+0.42%
Dentsu Group Inc.
BKRKF0.21N/A
N/A
Bank Rakyat
ZTSTF0.19N/A
N/A
ZTEST Electronics, Inc.
GRSLF0.19-0.01
-5.42%
GR SILVER MNG LTD.

FENC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, FENC has been loosely correlated with CLDX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if FENC jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FENC
1D Price
Change %
FENC100%
-1.03%
CLDX - FENC
44%
Loosely correlated
+0.20%
IDYA - FENC
44%
Loosely correlated
-0.33%
BEAM - FENC
41%
Loosely correlated
+3.30%
DNLI - FENC
40%
Loosely correlated
-7.26%
ARWR - FENC
40%
Loosely correlated
-3.53%
More